ATOS · Atossa Therapeutics, Inc.

This settlement directly addresses material legal risk to Atossa’s core intellectual property: two issued U.S. patents covering Endoxifen (Nos. 11,261,151 and 12,071,391) were under active challenge at the PTAB by Intas, threatening their validity and enforceability. By securing mutual non-challenge covenants and formalizing field-specific rights—including explicit preservation of Atossa’s development and commercialization rights in oncology, endocrine dysfunction, and muscular dystrophy—the agreement reduces near-term litigation uncertainty and strengthens the defensibility of its Z-endoxifen program. The anticipated PTAB termination reinforces the continued validity of these patents against third parties, which is critical for partnering, licensing, or future enforcement. While the filing does not disclose financial terms, the strategic impact is substantial: it removes a key overhang on clinical and commercial execution, supports ongoing regulatory and development planning, and enhances the asset’s value proposition in therapeutic areas where Atossa holds focused expertise. Forward-looking statements acknowledge risks related to PTAB implementation and broader clinical and regulatory execution, but the settlement itself represents a definitive resolution of an active, high-stakes IP conflict.